JP2002535407A - Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体 - Google Patents

Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体

Info

Publication number
JP2002535407A
JP2002535407A JP2000596008A JP2000596008A JP2002535407A JP 2002535407 A JP2002535407 A JP 2002535407A JP 2000596008 A JP2000596008 A JP 2000596008A JP 2000596008 A JP2000596008 A JP 2000596008A JP 2002535407 A JP2002535407 A JP 2002535407A
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
triazolo
pyridazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000596008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002535407A5 (cg-RX-API-DMAC7.html
Inventor
カーリング,ウイリアム・ロバート
カストロ・ピネイロ,ホセ・ルイス
ルイス,リチヤード・トーマス
ムーア,ケビン・ウイリアム
ストリート,レズリー・ジヨージフ
Original Assignee
メルク シャープ エンド ドーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901744.4A external-priority patent/GB9901744D0/en
Priority claimed from GBGB9901743.6A external-priority patent/GB9901743D0/en
Priority claimed from GBGB9912429.9A external-priority patent/GB9912429D0/en
Application filed by メルク シャープ エンド ドーム リミテッド filed Critical メルク シャープ エンド ドーム リミテッド
Publication of JP2002535407A publication Critical patent/JP2002535407A/ja
Publication of JP2002535407A5 publication Critical patent/JP2002535407A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000596008A 1999-01-27 2000-01-19 Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体 Withdrawn JP2002535407A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9901744.4A GB9901744D0 (en) 1999-01-27 1999-01-27 Therapeutic agents
GBGB9901743.6A GB9901743D0 (en) 1999-01-27 1999-01-27 Therapeutic agents
GB9901744.4 1999-05-27
GB9901743.6 1999-05-27
GB9912429.9 1999-05-27
GBGB9912429.9A GB9912429D0 (en) 1999-05-27 1999-05-27 Therapeutic agents
PCT/GB2000/000183 WO2000044752A1 (en) 1999-01-27 2000-01-19 Triazolo-pyridazine derivatives as ligands for gaba receptors

Publications (2)

Publication Number Publication Date
JP2002535407A true JP2002535407A (ja) 2002-10-22
JP2002535407A5 JP2002535407A5 (cg-RX-API-DMAC7.html) 2007-03-08

Family

ID=27269629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000596008A Withdrawn JP2002535407A (ja) 1999-01-27 2000-01-19 Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体

Country Status (9)

Country Link
US (2) US6500828B1 (cg-RX-API-DMAC7.html)
EP (1) EP1149102B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002535407A (cg-RX-API-DMAC7.html)
AT (1) ATE284403T1 (cg-RX-API-DMAC7.html)
AU (1) AU772947B2 (cg-RX-API-DMAC7.html)
CA (1) CA2359008C (cg-RX-API-DMAC7.html)
DE (1) DE60016566T2 (cg-RX-API-DMAC7.html)
ES (1) ES2232416T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000044752A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501346A (ja) * 2008-08-29 2012-01-19 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロ−ピリダジン誘導体

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000564D0 (en) 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
DE60315876T2 (de) * 2002-11-28 2008-05-21 Neurosearch A/S Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
JP2015516440A (ja) * 2012-05-11 2015-06-11 コンサート ファーマシューティカルズ インコーポレイテッド 7−(tert−ブチル−d9)−3−(2,5−ジフルオロフェニル)−6−((1−メチル−1H−1,2,4−トリアゾール−5−イル)メトキシ)−[1,2,4]トリアゾロ[4,3−b]ピリダジンの2型多形
WO2013170241A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
HUE060943T2 (hu) * 2018-09-13 2023-04-28 Saniona As A gaba A receptor ligandum
AU2023258030A1 (en) * 2022-04-20 2024-10-17 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
CN115837022B (zh) * 2023-02-20 2023-04-25 中山大学附属第八医院(深圳福田) 1,2,4三唑并4,3-b哒嗪衍生物在制备抗衰老药物中的应用
AU2024411621A1 (en) 2023-12-27 2026-06-18 Saniona A/S A gabaa receptor ligand and the use thereof in medicine, in particular in the treatment of epilepsy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0915875B1 (en) * 1996-07-25 2003-04-09 MERCK SHARP & DOHME LTD. Substituted triazolo-pyridazine derivatives as ligands for gaba receptors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501346A (ja) * 2008-08-29 2012-01-19 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロ−ピリダジン誘導体
JP2013100322A (ja) * 2008-08-29 2013-05-23 Concert Pharmaceuticals Inc 置換トリアゾロ−ピリダジン誘導体
JP2014058518A (ja) * 2008-08-29 2014-04-03 Concert Pharmaceuticals Inc 置換トリアゾロ−ピリダジン誘導体

Also Published As

Publication number Publication date
CA2359008A1 (en) 2000-08-03
CA2359008C (en) 2008-05-20
ES2232416T3 (es) 2005-06-01
US20030158203A1 (en) 2003-08-21
DE60016566T2 (de) 2005-12-15
WO2000044752A1 (en) 2000-08-03
ATE284403T1 (de) 2004-12-15
EP1149102A1 (en) 2001-10-31
DE60016566D1 (de) 2005-01-13
AU772947B2 (en) 2004-05-13
AU3066900A (en) 2000-08-18
US6500828B1 (en) 2002-12-31
EP1149102B1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
EP1149102B1 (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
EP1214319B1 (en) Imidazo-pyridine derivatives as ligands for gaba receptors
JP4749545B2 (ja) 置換トリアゾロ−ピリダジン誘導体、該誘導体から製造される医薬組成物
JP2002527519A (ja) Gaba受容体のリガンドとしてのピラゾロトリアジン誘導体
JP2004505086A (ja) Gaba受容体に対するリガンドとしてのイミダゾ−ピラジン誘導体
JP2003514907A (ja) Gaba受容体リガンドとしてのイミダゾ−ピリジン誘導体
JP2002501066A (ja) Gaba受容体に対するリガンドとしてのトリアゾロ−ピリダジン誘導体
JP2003516989A (ja) Gaba受容体リガンドとしてのピラゾロ−ピリジン誘導体
JP2002509150A (ja) Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体
JP2002501070A (ja) Gaba受容体のリガンドとしてのトリアゾロ−ピリダジン誘導体
JP2002518391A (ja) Gaba受容体のリガンドとしてのトリアゾロ−ピリジン誘導体
JP2003507479A (ja) Gaba受容体リガンドとしてのイミダゾ−トリアジン誘導体
JP2002501067A (ja) Gaba受容体に対するリガンドとしてのトリアゾロ−ピリダジン誘導体
JP2003508531A (ja) Gaba受容体のリガンドであるピリド−ピリダジン誘導体
JP2002518392A (ja) Gaba受容体のリガンドとしてのトリアゾロピリミジン類
US20030013716A1 (en) Pyrazino-pyridazine derivatives as ligands for gaba receptors
JP2002501071A (ja) Gaba受容体のリガンドとしてのトリアゾロ−ピリダジン誘導体
JP2002501069A (ja) Gaba受容体のためのリガンドとしてのトリアゾロ−ピリダジン誘導体
JP2002501068A (ja) Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体
JP2002536449A (ja) Gabaレセプターに対するリガンドとしてのトリアゾロ−ピリダジン誘導体
JP2002534418A (ja) GABA−Aα5受容体のリガンドとしてのテトラヒドロインダゾール誘導体
US20040242586A1 (en) 7-Tert-butyl-3-(2-fluoropenyl)-6-(2h(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo 4,3b)pyridazine for the treatment of anxiety and convulsions
AU2002331942A1 (en) 7-tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3-b) pyridazine for the treatment of anxiety and convulsions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070117

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091126